Novel pharmacotherapies for opioid use disorder and opioid withdrawal
Mary R. Shen, Kwadwo Owusu-Boaitey, Zackari D. Murphy, Alex N. Rains, Philip R. Wang, Dennis W. Zhou, Joji Suzuki · 2026
Read Novel pharmacotherapies for opioid use disorder and opioid withdrawal by Mary R. Shen, Kwadwo Owusu-Boaitey, Zackari D. Murphy, Alex N. Rains, Philip R. Wang, Dennis W. Zhou, Joji Suzuki (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13581858.txt.
Description
Seven authors, led by Mary Shen, review in 2026 new drug options for opioid use disorder and withdrawal. Three proven drugs exist, yet many patients drop out, cannot reach care, or still struggle. The review looks at drugs that act beyond the main opioid target in the brain.
Ketamine has early trial support for easing withdrawal and craving. A cannabis compound may blunt cue driven craving, while another may soften withdrawal signs. Psychedelic drugs show early signals but carry safety and legal bars. Gut hormone drugs used for diabetes are also under study. The authors weigh promise against proof for each class.
Catalog record
| CREATOR | Mary R. Shen, Kwadwo Owusu-Boaitey, Zackari D. Murphy, Alex N. Rains, Philip R. Wang, Dennis W. Zhou, Joji Suzuki |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 30 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |